{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T22:18:42Z","timestamp":1759702722819,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR6005-002"],"award-info":[{"award-number":["SHDC2020CR6005-002"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary central nervous system lymphoma (PCNSL) is an uncommon variant of non-Hodgkin lymphoma (NHL) with high aggressiveness and poor prognosis. Although complete remission (CR) could be achieved with therapy, some patients remain refractory or recurrently with a worse response to salvage treatment and poor prognosis. No consensus on rescue therapy has been established currently. This study is aimed to evaluate the efficacy of radiotherapy or chemotherapy in first-time relapsed or refractory progressed PCNSL (R\/R PCNSL) and analysis the prognostic factors, to explore differences between relapsed and refractory PCNSL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Totally 105 R\/R PCNSL patients from Huashan Hospital between 1 January 2016 and 31 December 2020 were enrolled, underwent salvage radiotherapy or chemotherapy and received response assessments after each course. PFS1 was defined as the time from diagnosis to the first time of recurrence or refractory progression. Statistical analysis was performed with SPSS version 26.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Response and survival were analyzed over a 17.5months (median) follow-up. Compared to relapsed PCNSL (<jats:italic>n<\/jats:italic> = 42), refractory PCNSL (<jats:italic>n<\/jats:italic> = 63) had a shorter median PFS1 related to deep lesions. 82.4% of cases were discovered as the second relapse or progression. ORR and PFS were both higher in relapsed PCNSL than those in refractory PCNSL. ORR of radiotherapy in both relapsed and refractory PCNSL was higher than that of chemotherapy. Elevated CSF protein and ocular involvement were related to PFS and OS after recurrence respectively in relapsed PCNSL. Age \u2265 60y was unfavorable to OS-R (OS after recurrence or progression) in refractory PCNSL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results indicate that relapsed PCNSL responds well to inducing and salvage therapy and has a better prognosis compared to refractory PCNSL. Radiotherapy is effective for PCNSL after the first relapse or progression. Age, CSF protein level, and ocular involvement could be potential factors to predict prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1098785","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:30:04Z","timestamp":1682573404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2598","article-title":"Primary central nervous system lymphoma: a curable disease","author":"Batchelor","year":"2019","journal-title":"Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5858\/132.11.1830","article-title":"Primary central nervous system lymphoma","volume":"132","author":"Bhagavathi","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23551","article-title":"The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large b-cell non-hodgkin's lymphoma","volume":"88","author":"O'neill","year":"2013","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93-10","volume":"20","author":"Deangelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2013.829634","article-title":"Recurrent or refractory primary central nervous lymphoma: therapeutic considerations","volume":"13","author":"Dahiya","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA)\u2020","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-cell therapy is effective but not long-lasting in b-cell lymphoma of the brain","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large b-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13667","article-title":"Treatment with temozolomide and ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"107","author":"Renaud","year":"2021","journal-title":"Eur J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012515","article-title":"Rituximab-Lenalidomide-Ibrutinib combination for Relapsed\/Refractory primary CNS lymphoma: a case series of the LOC network","volume":"97","author":"Houillier","year":"2021","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3564-6","article-title":"(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study","volume":"98","author":"Collignon","year":"2019","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large b-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.01.066","article-title":"Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy","volume":"80","author":"Ferreri","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15735","article-title":"Local control of primary dural central nervous system lymphoma achieved with radiotherapy","volume":"13","author":"Vallejo","year":"2021","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.11.001","article-title":"Primary non-hodgkin's lymphoma of the CNS treated with CHOD\/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors","volume":"59","author":"Bessell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.4.285","article-title":"Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large b-cell histology","volume":"52","author":"Ahn","year":"2017","journal-title":"Blood Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.20120844","article-title":"Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma","volume":"126","author":"Chen","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3892\/or.2018.6781","article-title":"Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma","volume":"41","author":"Zhuang","year":"2019","journal-title":"Oncol Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1098785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:30:10Z","timestamp":1682573410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1098785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":31,"alternative-id":["10.3389\/fonc.2023.1098785"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1098785","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"1098785"}}